Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Services
    Clinical Research ServicesCommercial PositioningConsultingEarly PhaseStrategic SolutionsLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read more
    Innovation
    FIRECRESTICON Digital PlatformSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGEMedical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMSICOMaster for eTMF
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Harmonising data and services for more integrated decentralised clinical trials.
    ICON Digital Platform

    Harmonising data and services for more integrated decentralised clinical trials.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    Watch the webinar
    Webinar: Regulatory considerations for technology in decentralised clinical trials

    Watch the webinar

    Watch the webinar
    Webinar: Social media data - Opportunities and insights for clinical research

    Watch the webinar

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON is committed to making a positive impact on our people, environment and our community.
    Environmental, Social & Governance

    ICON is committed to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 27 October 2017

    World's First Global Patient Outcomes Benchmarking Platform

    ICON and ICHOM unveil the world’s first global patient outcomes benchmarking platform

  • 27 July 2017

    ICON Acquires Mapi Group

    Mapi Group is a leading Patient-Centered Health Outcomes Research and Commercialisation company.

  • 6 July 2017

    ICON wins eLearning and Animation Awards for its FIRECREST Digital Solutions

    FIRECREST was awarded gold in the International eLearning Awards (IELA) in the blended learning category, and received a silver award for digital animation in the Summit International Awards.

  • 13 June 2017

    New Research Demonstrates Support for BYOD

    Research shows that commonly-cited equivalence and technical concerns around BYOD may not deter adoption.

  • 24 May 2017

    Best Partnership Award Win From Pharma Times

    ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimes

  • 11 May 2017

    ICON Named by Forbes as One of the Best Employers in America

    Forbes ranking of top employers drawn from a survey of 30,000 US employees in 25 industry sectors

  • 12 April 2017

    ICON Awarded Best CRO at World Vaccine Congress 2017

    ICON recognised for continually setting standards of excellence in vaccine development

  • 8 March 2017

    ICON Selected by ICHOM

    ICON and ICHOM are creating the world’s first global healthcare outcomes benchmarking programme

  • 20 February 2017

    Selected by the FDA to Validate Patient-Reported Outcome Endpoints

    Research is being conducted in collaboration with the FNIH Biomarkers Consortium. More details enclosed.

  • 16 December 2016

    ICON Honoured as Company of the Year at the Business & Finance Irish Business Awards

    Award recognises ICON’s business leadership, growth, innovation and employee development

  • 1
  • ...
  • 10
  • 11
  • 12
  • 13
  • 14
  • ...
  • 15
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON Spokespeople
  • Awards
  • Events
    • Industry events
      • SCOPE 2023
    • Webinars
    • Workshops
    • Financial Times Global Pharmaceutical and Biotechnology Conference
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2023 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies
  • International Transfers

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media